FGFR Agonist Dimeric Compounds for Receptor Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective synthetic molecules that can induce fibroblast growth factor receptor (FGFR) dimerization, which is crucial for activating cellular processes such as angiogenesis, muscle, bone, and hair-follicle regeneration.
Innovation Solution
Development of novel synthetic compounds with a dimeric structure that specifically induce FGFR dimerization, comprising two monomer units linked by a flexible linker group, allowing contact with extracellular binding sites of FGFR transmembrane receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural compounds (FGFs, PDGF, VEGF, etc.) are used to activate receptor dimerization, then biological activity is achieved, but the complexity of production and purification increases significantly
Solution Approach 1:
The patent creates simplified synthetic copies of natural ligands that retain the essential dimerization-inducing function. Instead of using complex natural compounds like FGFs (17-34 kDa proteins), the invention uses small synthetic molecules (formula I) that copy only the critical functional aspect - inducing receptor dimerization through a dimeric structure with appropriate spacing
Solution Approach 2:
The invention extracts and isolates the essential functional element from complex natural ligands - the dimeric structure capable of inducing receptor dimerization. The synthetic compounds of formula I contain only the necessary structural features (two monomer units linked by a linker) to activate the receptor, eliminating the need for complex protein structures, post-translational modifications, and purification processes
2Reliability
If FGF proteins (17-34 kDa) are used for therapy, then angiogenesis and tissue regeneration are promoted, but the cost and manufacturing difficulty increase
Solution Approach 1:
The patent employs small, stable synthetic molecules that are chemically robust and easier to manufacture than large proteins. The compounds of formula I can be synthesized through standard organic chemistry procedures, making them more accessible and potentially less expensive than recombinant FGF proteins, while maintaining the essential therapeutic function of inducing receptor dimerization
3Ease of manufacture
If no synthetic dimerization inducers are used, then manufacturing is simple, but effective FGFR activation cannot be achieved
Solution Approach 1:
The patent systematically optimizes the structural parameters of the synthetic compounds to achieve FGFR activation. The formula I compounds incorporate specific structural elements: monomer units with particular functional groups, linker groups with specific length and flexibility (2-20 links), and spatial arrangements that match the receptor binding geometry. These parameter optimizations enable synthetic compounds to effectively induce receptor dimerization
Solution Approach 2:
The synthetic compounds of formula I act as intermediary molecules that bridge the gap between simple chemical structures and complex biological function. The dimeric structure with appropriate linker length and flexibility serves as a mediator that can simultaneously engage two receptor monomers, inducing dimerization without requiring the complex protein-protein interactions of natural ligands
Data Source
AI summary
The invention relates to novel heterocyclic compounds which are pyrazolopyridine derivatives that induce FGFR dimerization, having the general formula: M -L-M 2 in which M and M 2, which may be identical or different, each represent, independently of one another, a monomer unit Mand L represents a linker group which links M1 and M2 covalently with the monomer unit which follows (Formula M). Process for the preparation thereof and therapeutic use thereof.